Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	225.18	77.39	170.2	62.53	50.19	12.88
Short-Term Investments	118.81	99.11	201.16	284.42	45.93	-
Cash & Short-Term Investments	343.99	176.5	371.36	346.95	96.12	12.88
Cash Growth	46.76%	-52.47%	7.04%	260.96%	646.43%	320.13%
Accounts Receivable	0.13	0.45	40.05	15.31	-	-
Other Receivables	0.1	0.1	0.5	0.5	-	-
Receivables	0.23	0.55	40.55	15.81	-	-
Inventory	-	-	38.32	9.77	-	-
Prepaid Expenses	9.16	12.38	14.43	9.61	5.39	0.76
Other Current Assets	-	-	-	-	3.44	-
Total Current Assets	353.38	189.43	464.67	382.13	104.95	13.64
Property, Plant & Equipment	5.88	2.73	6.41	8.14	0.47	0.15
Other Long-Term Assets	3.48	1.47	46.38	1.19	0.19	0.31
Total Assets	362.74	193.63	517.45	391.45	105.61	14.1
Accounts Payable	5.34	2.94	22.06	6.26	4.37	3.61
Accrued Expenses	19.47	23.95	57.72	38.31	13.02	3.71
Current Portion of Leases	0.98	1.52	2.26	2.04	-	-
Total Current Liabilities	25.79	28.41	82.04	46.61	17.4	7.33
Long-Term Debt	-	-	-	-	-	1.43
Long-Term Leases	4.95	0.46	1.98	4.24	-	-
Other Long-Term Liabilities	-	-	-	-	0.04	0.02
Total Liabilities	30.75	28.87	84.02	50.85	17.43	8.77
Common Stock	0.01	0.01	0.01	0.01	0	0
Additional Paid-In Capital	1,050	771.54	738.18	694.91	4.67	1.19
Retained Earnings	-718.43	-606.69	-304.95	-354.22	-155.85	-67.91
Comprehensive Income & Other	0.82	-0.09	0.2	-0.09	0.01	-
Total Common Equity	332	164.77	433.43	340.61	-151.17	-66.73
Shareholders' Equity	332	164.77	433.43	340.61	88.18	5.34
Total Liabilities & Equity	362.74	193.63	517.45	391.45	105.61	14.1
Total Debt	5.94	1.98	4.24	6.28	-	1.43
Net Cash (Debt)	338.06	174.52	367.13	340.67	96.12	11.45
Net Cash Growth	45.82%	-52.46%	7.77%	254.43%	739.31%	-
Net Cash Per Share	4.01	2.56	5.25	5.82	14.59	1.88
Filing Date Shares Outstanding	109.82	88.6	67.78	66.72	57.86	6.43
Total Common Shares Outstanding	109.77	68.63	66.51	66.51	7.02	5.99
Working Capital	327.59	161.03	382.62	335.52	87.56	6.31
Book Value Per Share	3.02	2.40	6.52	5.12	-21.53	-11.13
Tangible Book Value	332	164.77	433.43	340.61	-151.17	-66.73
Tangible Book Value Per Share	3.02	2.40	6.52	5.12	-21.53	-11.13
Machinery	-	1.92	3.55	2.17	0.34	0.05
Construction In Progress	-	0.22	0.59	0.8	0.14	0.06
Leasehold Improvements	-	0.18	0.18	0.18	0.05	0.04

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q